ASX Share rice
Thu 06 May 2021 - 07:51:am (Sydney)

CSL Share Price

CSL LIMITEDCSLPharmaceuticals, Biotechnology & Life Sciences

CSL Company Information


CSL Limited





GIC Industry:


GIC Sub Industry:



45 Poplar Road Parkville VIC Australia 3052


61 3 9389 1911

Full Time Employees:


MD, CEO & Exec. Director:

Mr. Paul R. Perreault B.A.

Chief Operating Officer:

Dr. Paul F. McKenzie

Sr. Adviser & Exec. Director:

Dr. Robert Andrew Cuthbertson A.O., BMedSci, MBBS, Ph.D., FTSE, FAHMS, AO

Chief Financial Officer:

Ms. Joy Carolyn Linton B.Com., BComm, Grad Dip AFI, GAICD

Head of Investor Relations:

Mr. Mark Dehring

Exec. VP of Legal & Group Gen. Counsel:

Mr. Gregory Boss B.S., BS(Hons), J.D.

Sr. Mang. of Communications:

Christina Hickie

Exec. VP & Chief HR Officer:

Ms. Elizabeth Walker B.A., M.S.

Exec. VP of Quality & Bus. Services:

Dr. Karen Etchberger

Head of Public Affairs:

Ms. Sharon McHale

Company Overview:

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

CSL Share Price Information

Shares Issued:


Market Capitalisation:


Dividend per Share:


Ex Dividend Date:


Dividend Yield:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Profit Margin:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


QuarterlyEarnings Growth(YOY):


CSL CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Borrowings:


Net Income:


Total Cash From Operating Activities:




Other Cashflow From Investing Activities:


Dividends Paid:


Change To Inventory:


Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


CSL Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Interest Expense:


Income Tax Expense:


Total Revenue:


Cost Of Revenue:


CSL Balance Sheet

Balance Sheet Date:


Intangible Assets:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Retained Earnings:


Other Liabilities:


Good Will:


Other Assets:




Total Current Liabilities:


Short-Term Debt:


Property - Plant & Equipment:


Net Tangible Assets:


Long-Term Investments:


Total Current Assets:


Long-Term Debt:


Net Receivables:


Short-Term Investments:




Accounts Payable:


Non Currrent Assets (Other):


Short-Term Investments:


Non Current Liabilities (Other):


Non Current Liabilities Total:


CSL Share Price History

CSL News

03 May, 2021
Seqirus, a global leader in influenza prevention, presented new Phase 3 clinical data demonstrating that the company's cell-based quadrivalent seasonal influenza vaccine (QIVc) was as safe and immunogenic as a standard quadrivalent seasonal influenza vaccine (QIV) in children six months through
29 Apr, 2021
Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The approval, based on data from the PATH (Polyneuropathy And Treatment with Hizentra) Extension study, simplifies dosage adjustments between two safe and effective doses proven to prevent CIDP relapse - without the need for intravenous immune globulin treatment in the event of a relapse on the low dose. The PATH Extension study was a multicenter, open-label extension study to the Phase III PATH study that evaluated the long-term safety and efficacy of Hizentra 0.2 g/kg and 0.4 g/kg weekly doses in the maintenance treatment of CIDP.
20 Apr, 2021
Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's MF59® adjuvanted, trivalent influenza vaccine (aTIV) in the peer-reviewed medical journal Clinical Infectious Diseases.1 Study results indicate aTIV was more effective in reducing influenza-related medical encounters compared with standard egg-based quadrivalent influenza vaccine (QIVe) and high-dose trivalent influenza vaccine (TIV-HD) among adults 65 years and older during the 2017/18 and 2018/19 U.S. influenza seasons.1
19 Apr, 2021
Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device began earlier this month, and introduction of the new platform is subject to U.S. Food and Drug Administration device clearance, at which time the parties will provide further comment.
About 12% of Haemonetics 2020 revenue came from a contract with CSL Plasma. CSL declined to renew the accord.
11 Apr, 2021
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
25 Mar, 2021
Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's cell-based quadrivalent seasonal influenza vaccine (QIVc) in peer-reviewed medical journal Vaccines.1 This retrospective cohort analysis indicated QIVc was more effective in reducing hospitalizations/emergency room (ER) visits caused by influenza, respiratory related hospitalizations/ER visits and all-cause hospitalizations compared with an egg-based quadrivalent influenza vaccine (QIVe) among individuals 4–64 years of age during the 2018/19 U.S. influenza season.1
23 Mar, 2021
Health Canada's Approval of FOCLIVIA® (An Adjuvanted, Egg-Based A Strain H5N1 Pandemic Influenza Vaccine) Meets Key Requirement as Pandemic PartnerMONTREAL, March 23, 2021 /CNW/ -- Seqirus, a world leader in influenza vaccines and pandemic response, announced today that following Health Canada's approval of FOCLIVIA® (adjuvanted, egg-based A strain H5N1 pandemic influenza vaccine), the Company is ready to fulfil its role in Canada's influenza pandemic preparedness plans.Seqirus Canada is an influenza pandemic vaccine partner to the Canadian Government through the Public Health Agency of Canada (PHAC).
18 Mar, 2021
MONTREAL, March 18, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, announced that Health Canada has approved FLUCELVAX® QUADRIVALENT (Influenza Vaccine), its cell-based quadrivalent influenza vaccine (QIVc), for an expanded age indication for people two years of age and older. Health Canada previously approved FLUCELVAX QUADRIVALENT for use in persons nine years of age and older.
09 Mar, 2021
In this article, we will take a look at the 15 Most Valuable Australian Companies. You can skip our detailed analysis of Australia’s economy and go to the 5 Most Valuable Australian Companies. Australia proved to be one of the most resilient economies in the wake of the coronavirus crisis. The Australian Bureau of Statistics (ABS) announced […]
05 Mar, 2021
Seqirus, a global leader in influenza prevention, today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the company's cell-based quadrivalent influenza vaccine (QIVc), for an expanded age indication for people two years of age and older.1 FLUCELVAX QUADRIVALENT was previously FDA-approved for use in persons four years of age and older. FLUCELVAX QUADRIVALENT will be available as a 0.5ml intramuscular (IM) vaccine per dose for the 2021/22 U.S. influenza season.
25 Feb, 2021
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CSL Limited ( ASX:CSL...
26 Jan, 2021
With its stock down 6.4% over the past three months, it is easy to disregard CSL (ASX:CSL). However, a closer look at...
25 Jan, 2021
Global biotherapeutics leader CSL Behring, and patient empowerment platform, Lyfebulb, announced today the launch of a first-of-its-kind online community support platform, TransplantLyfe, which is dedicated to providing transplant patients, their support partners and donors with the support they need in the transplant journey. Given the relatively low number of individuals undergoing an organ transplant each year, finding others with similar experiences in a local community can be difficult. By providing an active online community, solely focused on transplantation, TransplantLyfe enables connections with others who can relate and provide insights and advice.
12 Jan, 2021
Vaccines from Moderna and the team of Pfizer and BioNTech, in particular, have brought a possible end to the pandemic into sight. The pharma giant Merck (NYSE: MRK) has been especially slow to stir throughout the pandemic.
07 Jan, 2021
Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, unveils the launch of their 2021 Innovation Challenge: Thriving with Transplantation. The goal of this initiative is to source innovative solutions to improve outcomes and experiences for all those affected by organ transplantation.
15 Dec, 2020
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...
10 Dec, 2020
CSL Limited Sponsored ADR (CSLLY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
07 Dec, 2020
Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced the presentation of new data at the European Scientific Working Group on Influenza (ESWI) virtual conference, demonstrating the immunogenicity and safety of an adjuvanted, cell-based pandemic influenza A (H5N1) vaccine.1,2
Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced new late-breaking data from a systematic review and meta-analysis presented at the European Scientific Working Group on Influenza (ESWI) virtual conference confirming the benefit of an MF59®-adjuvanted trivalent seasonal influenza vaccine (aTIV) for adults 65 years and older.1 Results indicate that relative vaccine effectiveness (rVE) favored aTIV over non-adjuvanted standard dose quadrivalent and trivalent influenza vaccines in averting influenza-related medical encounters.1 aTIV was comparable to a high-dose TIV for the same outcome.1

CSL Dividend Payments

EX-Date Dividend Amount

CSL Dividends (last 12 Years)